Evidence map›Paper›PMID 35357513›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2022

Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results.

B Bukovszky, J Fodor, G Székely, S Zs Kocsis, F Oberna, T Major, Z Takácsi-Nagy, C Polgár, Z Jurányi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Head and neck squamous cell carcinoma in adults aged 45 or younger-an analysis of two tertiary cancer centres.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

B BukovszkyDepartment of Oncology, Semmelweis University, Budapest, Hungary. bukovszkybotond@gmail.com.ORCID 0000-0001-6418-5719
J FodorNational Institute of Oncology, Budapest, Hungary.
G SzékelyNational Institute of Oncology, Budapest, Hungary.
S Zs KocsisNational Institute of Oncology, Budapest, Hungary.
F ObernaNational Institute of Oncology, Budapest, Hungary.
T MajorDepartment of Oncology, Semmelweis University, Budapest, Hungary.
Z Takácsi-NagyDepartment of Oncology, Semmelweis University, Budapest, Hungary.
C PolgárDepartment of Oncology, Semmelweis University, Budapest, Hungary.
Z JurányiNational Institute of Oncology, Budapest, Hungary.
National Institute of Oncology · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the mutagen sensitivity phenotype on the risk of second primary cancer (SPC) in patients with head and neck squamous cell carcinoma (HNSCC), and to estimate the long-term rate of SPC and the outcome with SPC.

methodsA survey was made regarding SPC among 124 younger (≤ 50 years) adults with HNSCC who were enrolled in a pretreatment mutagen sensitivity investigation during 1996-2006. Mutagen sensitivity was assessed by exposing lymphocytes to bleomycin in vitro and quantifying the bleomycin-induced chromatid breaks per cell (b/c). Patients were classified as hypersensitive (> 1 b/c) or not hypersensitive (≤ 1 b/c).

resultsMean follow-up time for all patients was 68 months (range: 5-288 months), and the 15-year cancer-specific survival was 15%. Twenty patients (16%) developed a SPC (15-year estimated rate: 41%), and half of them was hypersensitive. The crude rate of SPC for hypersensitive (n = 65) or not hypersensitive (n = 59) patients were 15 and 17%, respectively (p = 0.4272). The 15-year estimated rate of SPC for hypersensitive and not hypersensitive patients was 36 and 48%, respectively (p = 0.3743). Gender, UICC stages, anatomical sites of index cancer did not prove to be a significant risk factor for SPC. Forty-five percent of SPC developed after the 10-year follow-up. The 3‑year cancer-specific survival was 23% with SPC.

conclusionAccording to our findings, mutagen hypersensitivity was not associated with an increased SPC risk in HNSCC patients. Patients are at a lifelong risk of developing a SPC. Survival with SPC is very poor.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsNeoplasms, Second PrimaryBleomycinEpithelial CellsHumansMutagensSquamous Cell Carcinoma of Head and NeckBleomycinMutagensBleomycin testHead and neck squamous cell cancerMutagen sensitivityRisk of second primary cancerSurvival with second primary cancer

Identifiers

PMID35357513
PMCPMC9402516
OpenAlexW4220725654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.